Growth-differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: The rancho bernardo study

Circulation

Volumn 123, Issue 19, 2011, Pages 2101-2110

  Daniels, Lori B ^a,c   Clopton, Paul ^a,b   Laughlin, Gail A ^a   Maisel, Alan S ^a,b   Barrett Connor, Elizabeth ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c MC 0607 ^*  (United States)

Author keywords

biomarker; elderly; GDF 15; mortality; natriuretic peptides

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; GROWTH DIFFERENTIATION FACTOR 15;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; COMMUNITY CARE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALIFORNIA; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 79957496852     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.979740     Document Type: Article

References (37)

1. Bootcov MR Bauskin AR Valenzuela SM Moore AG Bansal M He XY Zhang HP Donnellan M Mahler S Pryor K Walsh BJ Nicholson RC Fairlie WD Por SB Robbins JM Breit SN. MIC-1 a novel macrophage inhibitory cytokine is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci USA. 1997;94:11514-11519.
2. Fairlie WD Moore AG Bauskin AR Russell PK Zhang HP Breit SN. MIC-1 is a novel TGF-beta superfamily cytokine associated with macrophage activation. J Leukoc Biol. 1999;65:2-5.
3. Xu J Kimball TR Lorenz JN Brown DA Bauskin AR Klevitsky R Hewett TE Breit SN Molkentin JD. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res. 2006;98:342-350.
4. Su AI Wiltshire T Batalov S Lapp H Ching KA Block D Zhang J Soden R Hayakawa M Kreiman G Cooke MP Walker JR Hogenesch JB. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA. 2004;101:6062-6067.
5. Lawton LN Bonaldo MF Jelenc PC Qiu L Baumes SA Marcelino RA de Jesus GM Wellington S Knowles JA Warburton D Brown S Soares MB. Identification of a novel member of the TGF-beta superfamily highly expressed in human placenta. Gene. 1997;203:17-26.
6. Kempf T Eden M Strelau J Naguib M Willenbockel C Tongers J Heineke J Kotlarz D Xu J Molkentin JD Niessen HW Drexler H Wollert KC. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/ reperfusion injury. Circ Res. 2006;98:351-360.
7. Schlittenhardt D Schober A Strelau J Bonaterra GA Schmiedt W Unsicker K Metz J Kinscherf R. Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDLinduced apoptosis of human macrophages in vitro and in arteriosclerotic lesions. Cell Tissue Res. 2004;318:325-333.
8. Brown DA Lindmark F Stattin P Balter K Adami HO Zheng SL Xu J Isaacs WB Gronberg H Breit SN Wiklund FE. Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer. Clin Cancer Res. 2009;15:6658-6664.
9. Boyle GM Pedley J Martyn AC Banducci KJ Strutton GM Brown DA Breit SN Parsons PG. Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity. J Invest Dermatol. 2009;129:383-391.
10. Bauskin AR Brown DA Kuffner T Johnen H Luo XW Hunter M Breit SN. Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res. 2006;66:4983-4986.
11. Kempf T von Haehling S Peter T Allhoff T Cicoira M Doehner W Ponikowski P Filippatos GS Rozentryt P Drexler H Anker SD Wollert KC. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol. 2007;50:1054-1060.
12. Wollert KC Kempf T Peter T Olofsson S James S Johnston N Lindahl B Horn-Wichmann R Brabant G Simoons ML Armstrong PW Califf RM Drexler H Wallentin L. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation. 2007;115:962-971.
13. Kempf T Bjorklund E Olofsson S Lindahl B Allhoff T Peter T Tongers J Wollert KC Wallentin L. Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J. 2007;28:2858-2865.
14. Lind L Wallentin L Kempf T Tapken H Quint A Lindahl B Olofsson S Venge P Larsson A Hulthe J Elmgren A Wollert KC. Growthdifferentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J. 2009;30:2346-2353.
15. Brown DA Breit SN Buring J Fairlie WD Bauskin AR Liu T Ridker PM. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet. 2002;359:2159-2163.
16. Hypertension Detection and Follow-Up Program Cooperative Group. The Hypertension Detection and Follow-Up Program. Prev Med. 1976;5: 207-215.
17. Cockcroft DW Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
18. Vervoort G Willems HL Wetzels JF. Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation. Nephrol Dial Transplant. 2002; 17:1909-1913.
19. Friedewald WT Levy RI Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
20. Prentice RL Kalbfleisch JD Peterson AV Jr Flournoy N Farewell VT Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics. 1978;34:541-554.
21. Kremers WK. Concordance for survival time data: fixed and time-dependent covariates and possible ties in predictor and time. Technical Report Series 80.
22. -2007. http://mayoresearch.mayo.edu/biostat/upload/80.pdf. Accessed September 26 2010.
23. May S Hosmer DW. A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model. Lifetime Data Anal. 1998;4:109-120.
24. Pencina MJ D'Agostino RB Sr D'Agostino RB Jr Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157-172; discussion 207-112.
25. Pencina MJ D'Agostino RB Sr Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30:11-21.
26. Zimmers TA Jin X Hsiao EC McGrath SA Esquela AF Koniaris LG. Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury. Shock. 2005;23:543-548.
27. Khan SQ Ng K Dhillon O Kelly D Quinn P Squire IB Davies JE Ng LL. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur Heart J. 2009;30:1057-1065.
28. Bonaca MP Morrow DA Braunwald E Cannon CP Jiang S Breher S Sabatine MS Kempf T Wallentin L Wollert KC. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2011;31:203-210.
29. Koopmann J Buckhaults P Brown DA Zahurak ML Sato N Fukushima N Sokoll LJ Chan DW Yeo CJ Hruban RH Breit SN Kinzler KW Vogelstein B Goggins M. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res. 2004;10:2386-2392.
30. Welsh JB Sapinoso LM Kern SG Brown DA Liu T Bauskin AR Ward RL Hawkins NJ Quinn DI Russell PJ Sutherland RL Breit SN Moskaluk CA Frierson HF Jr Hampton GM. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci USA. 2003;100:3410-3415.
31. Brown DA Ward RL Buckhaults P Liu T Romans KE Hawkins NJ Bauskin AR Kinzler KW Vogelstein B Breit SN. MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res. 2003;9:2642-2650.
32. Lee DH Yang Y Lee SJ Kim KY Koo TH Shin SM Song KS Lee YH Kim YJ Lee JJ Choi I Lee JH. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res. 2003;63: 4648-4655.
33. Shnaper S Desbaillets I Brown DA Murat A Migliavacca E Schluep M Ostermann S Hamou MF Stupp R Breit SN de Tribolet N Hegi ME. Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome. Int J Cancer. 2009; 125:2624-2630.
34. Ferrari N Pfeffer U Dell'Eva R Ambrosini C Noonan DM Albini A. The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide. Clin Cancer Res. 2005;11:4610-4619.
35. De Ruijter W Westendorp RG Assendelft WJ den Elzen WP De Craen AJ le Cessie S Gussekloo J. Use of Framingham Risk Score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. BMJ. 2009;338:a3083.
36. Kannel WB D'Agostino RB. The importance of cardiovascular risk factors in the elderly. Am J Geriatr Cardiol. 1995;4:10-23.
37. Hlatky MA Greenland P Arnett DK Ballantyne CM Criqui MH Elkind MS Go AS Harrell FE Jr Hong Y Howard BV Howard VJ Hsue PY Kramer CM McConnell JP Normand SL O'Donnell CJ Smith SC Jr Wilson PW. Criteria for evaluation of novel markers of cardiovascular risk: a Scientific Statement from the American Heart Association. Circulation. 2009;119:2408-2416.